JP2025509830A - 血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用 - Google Patents

血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用 Download PDF

Info

Publication number
JP2025509830A
JP2025509830A JP2024555344A JP2024555344A JP2025509830A JP 2025509830 A JP2025509830 A JP 2025509830A JP 2024555344 A JP2024555344 A JP 2024555344A JP 2024555344 A JP2024555344 A JP 2024555344A JP 2025509830 A JP2025509830 A JP 2025509830A
Authority
JP
Japan
Prior art keywords
compound
formula
mouse
body weight
mpk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509830A5 (https=
Inventor
ショジャエイ，ファーボッド
ファング，チェ
センプレ，ジェイ．エドワード
ギリングス，ミレイユ
Original Assignee
フヤバイオ インターナショナル，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フヤバイオ インターナショナル，エルエルシー filed Critical フヤバイオ インターナショナル，エルエルシー
Publication of JP2025509830A publication Critical patent/JP2025509830A/ja
Publication of JP2025509830A5 publication Critical patent/JP2025509830A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024555344A 2022-03-14 2023-03-10 血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用 Pending JP2025509830A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263319589P 2022-03-14 2022-03-14
US63/319,589 2022-03-14
PCT/US2023/015021 WO2023177592A1 (en) 2022-03-14 2023-03-10 Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2025509830A true JP2025509830A (ja) 2025-04-11
JP2025509830A5 JP2025509830A5 (https=) 2026-03-16

Family

ID=88024124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555344A Pending JP2025509830A (ja) 2022-03-14 2023-03-10 血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用

Country Status (7)

Country Link
US (1) US20230293539A1 (https=)
EP (1) EP4493184A4 (https=)
JP (1) JP2025509830A (https=)
KR (1) KR20250009417A (https=)
CA (1) CA3245866A1 (https=)
MX (1) MX2024011346A (https=)
WO (1) WO2023177592A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025090881A1 (en) * 2023-10-27 2025-05-01 Huyabio International, Llc Combination therapies of wdr5 inhibitors and pd-1 inhibitors
WO2026058961A1 (en) 2024-09-13 2026-03-19 Alivexis, Inc. Wdr5 inhibitors, compounds, pharmaceutical compositions, and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063058B2 (en) * 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US11319299B2 (en) * 2016-03-01 2022-05-03 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
CN107382840B (zh) * 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
WO2019046944A1 (en) * 2017-09-06 2019-03-14 Propellon Therapeutics Inc. INHIBITORS OF PROTEIN BINDING WDR5-PROTEIN
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
EP4523755A3 (en) * 2018-09-18 2025-06-11 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
CN109734674B (zh) * 2019-02-26 2022-08-26 中国药科大学 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
TWI899080B (zh) * 2019-05-27 2025-10-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑

Also Published As

Publication number Publication date
KR20250009417A (ko) 2025-01-17
CA3245866A1 (en) 2023-09-21
WO2023177592A1 (en) 2023-09-21
MX2024011346A (es) 2025-01-09
EP4493184A1 (en) 2025-01-22
EP4493184A4 (en) 2026-03-18
US20230293539A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US10568884B2 (en) Compounds and compositions as protein kinase inhibitors
JP5143916B2 (ja) 新規２環性複素環化合物
EP3584239B1 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
EP3992189A1 (en) Quinazoline and cinnoline derivatives as dna-pk inhibitor
WO2019042445A1 (zh) 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
JP2025514382A (ja) Ｒｏｃｋ２の阻害剤
JP2025509830A (ja) 血液脳関門を通過するｍｌｌ１－ｗｄｒ５タンパク質間相互作用阻害剤化合物及びそれらの使用
JP2025509846A (ja) フェニルトリアゾールｍｌｌ１－ｗｄｒ５タンパク質－タンパク質間相互作用阻害剤
KR102690225B1 (ko) 퀴놀린 함유 화합물, 의약 조성물 및 그의 용도
US20070244110A1 (en) Treatment of prostate cancer, melanoma or hepatic cancer
EP4539936A1 (en) Prodrugs of stat3 inhibitors
US20230095530A1 (en) Compound used as ret kinase inhibitor and application thereof
WO2022200576A1 (en) Indoline derivatives as ddr1 and ddr2 inhibitors
US11660303B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
KR20200142245A (ko) 신규한 인다졸 유도체 화합물 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN121443598A (zh) 蛋白酪氨酸磷酸酶抑制剂及其组合物、医药用途
CN117263950A (zh) 一种哒嗪类化合物、其药物组合物及应用
WO2017164173A1 (ja) イミダゾール化合物及びこれを含有する医薬
HK1191936A (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260306